Current GMP Standards for the Production of Vaccines and Antibodies: An Overview

Overview

Journal Front Public Health

Specialty Public Health

Date 2023 Feb 6

PMID 36743162

Authors

Consuelo E Covarrubias

Thomas A Rivera

Catalina A Soto

Trevor Deeks

Alexis M Kalergis

Affiliations

Soon will be listed here.

Abstract

The manufacture of pharmaceutical products made under good manufacturing practices (GMP) must comply with the guidelines of national regulatory bodies based on international or regional compendia. The existence of this type of regulation allows pharmaceutical laboratories to count on the standardization of high-quality production processes, obtaining a safe product for human use, with a positive impact on public health. In addition, the COVID-19 pandemic highlights the importance of having more and better-distributed manufacturing plants, emphasizing regions such as Latin America. This review shows the most important GMP standards in the world and, in particular, their relevance in the production of vaccines and antibodies.

Citing Articles

Serum-Free Suspension Culture of the C6/36 Cell Line for Chimeric Orthoflavivirus Vaccine Production.

Dawurung J, Harrison J, Modhiran N, Hall R, Hobson-Peters J, de Malmanche H Viruses. 2025; 17(2).

PMID: 40007005 PMC: 11860912. DOI: 10.3390/v17020250.

Good manufacturing practice inspections conducted by Tanzania medicines and medical devices authority: a comparative study of two fiscal years from 2018 to 2020.

Sangeda R, Ndabatinya C, Maganga M, Nkiligi E, Mwalwisi Y, Fimbo A J Pharm Policy Pract. 2024; 17(1):2399722.

PMID: 39291054 PMC: 11407403. DOI: 10.1080/20523211.2024.2399722.

Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.

Waugh S, Cameron C Hum Vaccin Immunother. 2024; 20(1):2399915.

PMID: 39262177 PMC: 11404580. DOI: 10.1080/21645515.2024.2399915.

The Platform Technology Approach to mRNA Product Development and Regulation.

Skerritt J, Tucek-Szabo C, Sutton B, Nolan T Vaccines (Basel). 2024; 12(5).

PMID: 38793779 PMC: 11126020. DOI: 10.3390/vaccines12050528.

Quality control in SARS-CoV-2 RBD-Fc vaccine production using LC-MS to confirm strain selection and detect contaminations from other strains.

Suwanchaikasem P, Rattanapisit K, Strasser R, Phoolcharoen W Sci Rep. 2024; 14(1):9629.

PMID: 38671013 PMC: 11053075. DOI: 10.1038/s41598-024-59860-4.

References

Barkan I . Industry invites regulation: the passage of the Pure Food and Drug Act of 1906. Am J Public Health. 1985; 75(1):18-26. PMC: 1646146. DOI: 10.2105/ajph.75.1.18. View

Noblett K, Crowder C . Neuromodulation. Obstet Gynecol Clin North Am. 2021; 48(3):677-688. DOI: 10.1016/j.ogc.2021.05.018. View

Chinnasami B, Sadasivam K, Vivekanandhan A, Arunachalam P, Pasupathy S . A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children. J Clin Diagn Res. 2015; 9(5):SC01-3. PMC: 4484117. DOI: 10.7860/JCDR/2015/13302.5903. View

Si Lim S, Grupp S, DiNofia A . Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021; 68(9):e29123. DOI: 10.1002/pbc.29123. View

Rey-Jurado E, Soto J, Galvez N, Kalergis A . A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus. Hum Vaccin Immunother. 2017; 13(9):2092-2097. PMC: 5612508. DOI: 10.1080/21645515.2017.1334026. View

Koga M, Senkoji T, Kubota M, Ishizaka A, Mizutani T, Sedohara A . Predictors associated with a better response to the Japanese aluminum-free hepatitis A vaccine, Aimmugen , for people living with HIV. Hepatol Res. 2021; 52(3):227-234. DOI: 10.1111/hepr.13736. View

Hinman A, Orenstein W, Rodewald L . Financing immunizations in the United States. Clin Infect Dis. 2004; 38(10):1440-6. DOI: 10.1086/420748. View

Cespedes P, Gonzalez P, Kalergis A . Human metapneumovirus keeps dendritic cells from priming antigen-specific naive T cells. Immunology. 2013; 139(3):366-76. PMC: 3701183. DOI: 10.1111/imm.12083. View

Bueno S, Abarca K, Gonzalez P, Galvez N, Soto J, Duarte L . Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv. 2022; . PMC: 9016657. DOI: 10.1101/2021.03.31.21254494. View

10.

Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S . Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. J Med Chem. 2022; 65(9):6499-6512. PMC: 8982737. DOI: 10.1021/acs.jmedchem.2c00117. View

11.

Merino J, Macho-Gonzalez A, Benedi J, Gonzalez M . Neurological manifestations of COVID-19 in patients: from path physiology to therapy. Neurol Sci. 2021; 42(12):4867-4879. PMC: 8379040. DOI: 10.1007/s10072-021-05505-7. View

12.

Villanueva P, Wadia U, Crawford N, Messina N, Kollmann T, Lucas M . The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines. PLoS One. 2022; 17(6):e0268042. PMC: 9165819. DOI: 10.1371/journal.pone.0268042. View

13.

Rathore A, Bhargava A . Regulatory considerations in biosimilars: Asia pacific regions. Prep Biochem Biotechnol. 2020; 51(1):1-8. DOI: 10.1080/10826068.2020.1815061. View

14.

Bueno S, Gonzalez P, Cautivo K, Mora J, Leiva E, Tobar H . Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A. 2008; 105(52):20822-7. PMC: 2634951. DOI: 10.1073/pnas.0806244105. View

15.

Duong D, Vogel L . Why is WHO pushing back on a Health Canada-approved Medicago SARS-CoV-2 vaccine?. CMAJ. 2022; 194(13):E504-E505. PMC: 8985905. DOI: 10.1503/cmaj.1095992. View

16.

Kinaciyan T, Nagl B, Faustmann S, Kopp S, Wolkersdorfer M, Bohle B . Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy. Allergy. 2015; 71(2):272-4. PMC: 4722287. DOI: 10.1111/all.12781. View

17.

Shah S, Alsaab H, Rawas-Qalaji M, Uddin M . A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines (Basel). 2021; 9(10). PMC: 8540464. DOI: 10.3390/vaccines9101086. View

18.

Rauber M, Mobs C, Campana R, Henning R, Schulze-Dasbeck M, Greene B . Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells. Allergy. 2019; 75(2):450-453. DOI: 10.1111/all.13996. View

19.

Huber V, McCullers J . FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther. 2008; 10(1):75-85. View

20.

Soto J, Diaz F, Retamal-Diaz A, Galvez N, Melo-Gonzalez F, Pina-Iturbe A . BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and . Vaccines (Basel). 2022; 10(5). PMC: 9143576. DOI: 10.3390/vaccines10050721. View